Trial Search Results

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

This study is being done to test the safety and effectiveness of brentuximab vedotin and nivolumab when given in combination. This clinical trial uses 2 drugs, one called brentuximab vedotin and the other called nivolumab. The Food and Drug Administration (FDA) has approved both brentuximab vedotin and nivolumab for sale in the United States for certain diseases. Brentuximab vedotin and nivolumab are still being studied in research studies like this one to find out what their side effects are and whether or not they are effective together in some diseases, such as Hodgkin lymphoma.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Seattle Genetics, Inc.

Collaborator: Bristol-Myers Squibb

Intervention(s):

  • Drug: brentuximab vedotin
  • Drug: nivolumab

Phase:

Phase 1/Phase 2

Eligibility


Inclusion Criteria:

   - Relapsed or refractory Hodgkin lymphoma following failure of standard frontline
   chemotherapy for the treatment of classical Hodgkin lymphoma

   - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

   - Previously treated with brentuximab vedotin, immune-oncology agents, or received an
   allogeneic or autologous stem cell transplant

   - Documented history of a cerebral vascular event

   - History of another invasive malignancy that has not been in remission for at least 3
   years

   - History of progressive multifocal leukoencephalopathy (PML)

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting